HealthQuill Verve Therapeutics
Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an early-stage experimental therapy and to develop once-in-a-lifetime treatments for cardiovascular diseases.
Drugs Health Pharma

Eli Lilly to buy Verve for $1.3 billion, expands heart therapy segment

HQ Team June 19, 2025: Eli Lilly and Company will acquire gene-editing startup Verve Therapeutics, Inc. for up to $1.3 billion to pocket an.

Read More